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1.INTRODUCTION 
 
1.1 Hematopoietic stem cells (HSC)  
In humans, the hematopoietic system is a highly structured hierarchy which 
originates from hematopoietic stem cells (HSC). HSCs are characterized by the 
peculiar and unique ability to self-renew and differentiate into mature and 
functional blood cells of many different lineages. Moreover, they are capable of 
reconstituting the hematopoietic system in recipients after myeloablative irradiation 
1
.  From  a numerical point of view, HSC is a rare population, accounting for 1 in 
10000 to 1000000 cells in BM. They are physiologically quiescent but upon 
stimulation, they can enter into cell cycle and proliferate. These processes are 
strongly and deeply regulated, resulting, whenever abnormal regulation of HSC cell-
fate occurs, in leukemia and other myeloproliferative disorders. 
The studies of molecular marker expression performed by flow cytometry analysis 
have led the identification of each blood cell subpopulations in terms of their 
biology and potential when combined with other functional assays. As a result, 
schematic demonstration of hematopoietic hierarchy has been proposed (Figure 1). 
The origin of all blood cell in hematopoietic system is thought to be derived from 
HSCs that contain self-renewal capacity and give rise to multipotent progenitors 
(MPPs) which lose self-renewal potential but remain fully differentiate into all 
multilineages. MPPs further give rise to oligopotent progenitors which are 
represented by common lymphoid and myeloid progenitors (CLPs and CMPs, resp.). 
All these oligopotent progenitors therefore differentiate into their restricted lineage 
commitment: (1) CMPs advance to megakaryocyte/erythrocyte progenitors (MEPs), 
granulocyte/macrophage progenitors (GMPs), and dendritic cell (DC) progenitors, 
(2) CLPs give rise to T cell progenitors, B cell progenitors, NK cell progenitors and DC 
progenitors.  
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Figure 1: Hierarchy of hematopoiesis. The phenotypic cell surface marker of each population of 
human blood system is shown.  
 
                              
1.2 Cancer Stem Cells  
 
Treatment of cancer still represents an ambitious challenge, since, both in solid and 
in haematological setting, the pathogenesis involves dysregulation of endogenous 
and essential cellular processes 
2
. These alterations determine the difficulty, shared 
worldwide by scientists and physicians, to identify the potential targets to be hit in 
order to eradicate many neoplastic diseases. 
According to the most recent literature, the development and maintenance of 
cancer can be explained by two different models. One model is the so called 
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“stochastic model”, in which all cancer cells are able to form and maintain the tumor 
mass (Figure 2a). The second model, the so called “hierarchical model”, identifies a 
small group of cells susceptible for transformation, which forms and maintains the 
tumor (Figure 2b). The hierarchical model is also called the “cancer stem cell” (CSC) 
model because the group of cells responsible for this maintenance of the tumor has 
stem cell like characteristics 
3, 4, 5
 
 
 
Figure 2 Two general model of heterogeneity in cancer cells. 
a) “Stochastic model”: cancer cells of many different phenotypes have the potential to proliferate 
extensively, but any one cell would have a low probability of exhibiting this potential in an assay of 
clonogenicity or tumorigenicity. b) “Hierarchical model”: most cancer cells have only limited 
proliferative potential, but a subset of cancer cells consistently proliferate extensively in 
clonogenic assays and can form new tumors upon transplantation. This model  predicts that a 
distinct subset of cells is enriched for the ability to form new tumors, whereas most cells are 
depleted of this ability. Existing therapeutic approaches, both in leukemia and in solid tumors, 
have been based largely on the first described model, but the failure of these treatments to 
eradicate most solid cancers suggests that the second mode may be more accurate
6
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More and more increasing evidences have been found, supporting the CSC 
hypothesis, and many features suggest an overlap between SCs and CSCs 
6
.  
In details, normal SCs have the ability to proliferate life-long, are immortal and are 
mostly resistant to drugs by multiple mechanisms. SCs can divide asymmetrically 
and produce two cells: a daughter SC and a progenitor cell that can differentiate into 
different lineages but cannot self-renew. SCs have specific markers and are able to 
differentiate into certain tissues and cells due to the microenvironment and other 
factors.  
CSCs are quite similar to these criteria. CSCs have the ability to proliferate and the 
peculiar property to self-renew, and are heterogeneous. The CSC develops along the 
differentiation path similar as normal SCs and finally the tumor includes tumor 
initiating cells (CSCs) and an abundant amount of non-tumor initiating cells. CSCs 
express specific markers, often also found on SCs and importantly CSCs are often 
more resistant to drugs then the bulk of the tumor 
7, 8
.  
The main evidences for the existence of CSC emerge from in vitro and in vivo 
experiments. Bonnet et al., in the mid-1990s, identified a stem cell-like population 
from a human acute myeloid leukemia (AML), proving that cells with the 
CD34+/CD38- phenotype are the cells that are able to proliferate and initiate AML. 
This population of cells represent 0.2% of the human leukemia population
5
. The 
isolated cells, CD34+CD38-, had a similar cell-surface phenotype to normal SCID-
repopulating cells. They showed that these stem-like cells were capable of initiating 
human AML in NOD/SCID mice. In addition, the data they collected suggested that 
normal primitive cells, rather than committed progenitor cells, are targets for 
leukemic transformation. These cells homed to the bone marrow and proliferated 
extensively in response to in vivo cytokine treatment, resulting in a pattern of 
dissemination and leukemic cell morphology similar to that seen in the original 
patients 
9
.  
7 
 
Therefore, Zou postulated the definition of the CSC as follows: 
“Cancer stem cells can be defined as the specific cell population inside cancer which 
has the capacity for self-renewal, the potential to develop into any cells in the overall 
tumor population, and the proliferative ability to drive continued expansion of the 
population of malignant cells.”
10
. 
It is not known whether CSCs really arise from SCs however it is possible that 
deregulation of the normal SC gives the development of cancer
9
. Tumorigenesis 
process begins either with transformation of a multipotent SC which leads to 
uncontrolled self-renewal or transformation of a more downstream progenitor cell 
leading to acquired self-renewal of a cell that did not have self-renewal capacity 
6,11
  
In 1988, Pierce and Speers defined the CSC concept as follows: 
“A concept of neoplasms, based upon developmental and oncological principles, 
states that carcinomas are caricatures of tissue renewal, in that they are composed 
of a mixture of malignant stem cells, which have a marked capacity for proliferation 
and a limited capacity for differentiation under normal homeostatic conditions, and 
of the differentiated, possibly benign, progeny of these malignant cells.” 
12
 
Recently, and to summarize, Weissman and colleagues have proposed that a 
candidate CSC population should exhibit the following properties:  
1) The unique ability to engraft;  
2) The ability to recapitulate the tumor of origin both morphologically and 
immunophenotypically in xenografts;  
3) The ability to be serially transplanted
13
. 
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1.3 Leukemic Stem Cells (LSCs) in AML 
 
AML represents a group of  clinically, cytogenetically and molecularly  
heterogeneous diseases, affecting mostly adult people worldwide, with a mild 
prevalence in male sex and an estimated incidence of 3,7 cases out of 100,000 
persons. The pathogenesis of this rare disease involves a block of differentiation at 
the myeloid lineage, which results into growth of abnormal white blood cells called 
blasts, which disrupt the growth of normal blood cells, white and red blood cells. 
This leads to a default in the immune system resulting in infections, bleeding or 
organ infiltration and a defect in the formation of red blood cells resulting in 
anaemia. AML patients outcome are very poor, mainly in elderly subgroups, unfit for 
aggressive chemotherapeutic approaches and allogeneic stem cell transplantation.   
The AML phenotype is extremely various, since the disease develops by sudden 
genetic and/ or epigenetic events leading to the transformation of the HSC or 
progenitor. In the case of transformation of the progenitor, LSCs maintain the 
identity of the progenitor from which they arose, while acquiring SC-like features 
such as self-renewal 
14
. The phenotype of the LSC is much more heterogeneous than 
expected and can vary even within a single AML sample.  
At present, in AML treatment, despite a high initial complete remission rate 
obtained after induction chemotherapy, many patients relapse afterwards, resulting 
in a still dismal overall outcome. Several relapse related factors have been so far 
identified, such as certain cytogenetic and molecular aberrations at diagnosis, lack 
of early treatment response and high level of minimal residual disease (MRD, small 
number of leukemic cells that remain in the patient) after treatment. Moreover, 
high frequencies of LSCs at diagnosis and after treatment have been shown to 
predict relapse in AML
15
. Indeed, since conventional intensive chemotherapy 
primarily targets at the proliferative leukemic blasts, it has led to the concept of 
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chemo-resistant leukemia initiating cells, which can give rise to leukemic blasts and 
hence sustain the haematological malignancy.  
Quiescence of LSCs, also called dormancy, is probably the most important reason for 
treatment failure of AML cells because these cells are not in cycle. As known, most 
conventional chemotherapy (e.g. anthracyclines, cytarabine) triggers cell death by 
inducing DNA damage which leads to interference with cell growth and keeping the 
cells in S-phase resulting in the induction of cell death. Therefore, rapid dividing cells, 
such as tumor cells, are most affected by chemotherapy. The LSC are non-cycling. 
Therefore, most chemotherapeutic agents do not trigger cell death in these cells as 
easy as in rapidly dividing cells. The LSC escapes the induction of cell death, resulting 
in disease relapse. After chemotherapy treatment in AML, quiescent LSC’s often 
survive because of their dormant properties.  
It’s still a very debating object the development of agents which could bring normal 
SCs into cell cycle and awake the quiescent cells. To the best of our knowledge, 
some Cytokines like Interferon (INF)α and granulocyte colony stimulating factor (G-
CSF) are able to activate HSCs. Moreover, the compound arsenic trioxide (As2O3), 
which is very active in APL, both at diagnosis and at relapse, targets the 
promyelocytic leukemia (PML) protein resulting in degradation of the protein and 
the increase of mRNA 15. This results, like INFα and G-CSF, in cells getting into cycle. 
The initial stem cell idea of leukemia stem cell was first iterated in 1981, when 
Fialkow et al first demonstrated the clonal nature of AML by X-linked inactivation 
gene pattern 
16
. 
Following published studies, showed that only a small percentage of AML blast cells 
can proliferate and form colonies in in vitro methylcellulose culture 
17,
 
18
.  
Thereafter, Bonnet D and Dick JE, as already mentioned, firstly demonstrated the 
existence of putative LSC by showing that irrespective of the morphologic subtypes, 
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only a small fraction of LSCs, bearing the HSC-like phenotype (CD34+CD38-), can 
recapitulate the leukemia when injected into sublethally irradiated NOD/SCID mice 
5
.  
Based on this discovery, Acute myeloid leukemia (AML) would be initiated and 
maintained by a small population of cells that have SC-like characteristics (Figure 3). 
These cells proliferate, divide asymmetrically and are able to self-renew and are 
called LSCs 
19,20
. Due to their persistence despite the administration of high dosage 
chemotherapy schedules, it is essential to develop new therapeutic strategies to 
eradicate LSCs.  
LSCs are located at the endosteal region of the bone marrow and are mainly non-
cycling 
21,
 
22,
 
23
. Due to this quiescent property, their escape from therapy could be 
explained. Thus, their release from this quiescence state could represent an 
opportunity to lead the LSCs into cell death.  
As previously described, LSCs and normal HSCs share several features, since they 
both reside in the AML bone marrow and present similar cell surface markers. The 
success of anti-LSC therapy would rely on functional manipulation of genes that lead 
to specific killing of LSCs while saving normal HSCs (Figure 4). 
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Figure 3 Leukemic stem cells may be targeted by a two-step strategy. Leukemic stem cells (LSCs), 
which may be a minority within the leukemic clone, show significant resistance to anti proliferative 
chemotherapy regimes that are thought to be the cause of frequently observed tumor relapse. In 
analogy to normal dormant hematopoietic stem cells (HSCs), resistance of LSCs may, at least in 
part, be mediated by a state of deep dormancy. Thus to specifically target dormant LSCs one may 
postulate a two-step therapy model. First, dormant LSCs would be activated by factors, such as 
Interferon α (IFNα), granulocyte colony-stimulating factor (G-CSF) or arsenic trioxide (As2O3) and 
exit from their niche. Once they are cycling, treatment would be continued through administration 
of targeted chemotherapy, such as Imatinib or cytarabine 
19
. 
 
 
At present, the characteristics of LSC have not yet been fully and clearly defined. 
From the mid 90’s, many studies have identified, in AML, potential phenotypic 
signatures which might concur in the definition of a LSC panel. Among these, Blair 
and co-authors  showed that AML LSCs were highly enriched in the CD34+CD38–
CD90–CD117– population 
24, 25
.  
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Figure 4 Development of LSC in AML. AML is organized in a hierarchy as normal hematopoiesis. 
Leukemic transformation into LSC can occur either at the primitive HSC level, multipotent 
progenitor (MMP), or even at the committed progenitor levels (CMP and GMP). Leukemic blasts of 
the different subtypes of AML (M0-M7) arise from a block in differentiation along the various 
hematopoietic lineages. 
 
 
More recently, LSC have been characterized based on other phenotypic markers, 
including interleukin-3 (IL-3) receptor CD123 
26
, early myeloid antigen CD33
27
, the C-
type lectin-like molecule-1 (CLL-1)
28
, the pan-T cell marker CD96
29
 and CD44
30
 (Table 
13 
 
1). These data result in the lack of a unique surface phenotype in LSC population, 
suggesting that additional functional markers may be important in defining LSC. 
 
Table 1 Surface phenotype of LSC 
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1.3.1 Regulations of LSC in AML 
 
Many studies, performed on transgenic mouse models and exogenous gene 
manipulatons, have identified a number of genes involved in regulating LSC in Acute 
Leukemia setting. Among these, the overexpression of HOXA9 in donor mouse BM 
cells, and resulted in long latency leukemia in recipient after transplantation have 
been demonstrated
31
. Moreover, deletion of the polycomb group gene PTEN in 
murine HSC has been showed to led to the rapid development of myeloproliferative 
disease and eventually leukemia that are transplantable into secondary recipients 
32
. 
Interestingly, human lin- UCB cells that were retrovirally transduced with the mixed-
lineage leukemia (MLL)-AF9 fusion might be able to induce both acute lymphoid 
leukemia (ALL) and AML upon transplantation into immunodeficient mice 
33
. 
Many other relevant studies have been conducted in primary AML samples, in order 
to identify the altered expression of genes and the involvement of the related 
signalling pathways in maintaining LSCs.   
For instance, CD34+ AML cells have been showed to present at least three activated 
pathways, if compared with normal HSC: 
-Activated NF kappa B activity 
34
;  
-Activated phosphoinositide 3-kinase (PI3K) 
35
  
-Constitutive activated Wnt/β-catenin pathway 
36
  
Recent studies have also shown that, analogous to HSC, LSCs from AML homed to 
and engrafted in the BM endosteal region upon transplantation into 
immunodeficient Mice 
23
. More importantly, it has been demonstrated by the same 
authors that chemoresistant leukemic cells were clustered around the putative HSC 
niches in the BM endosteum and the sinusoidal endothelium
23
. This has highlighted 
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the important role of the BM microenvironment in regulating LSC. In addition, gene 
expression analysis have been performed, and data obtained have also revealed 
changes in the molecular signatures in leukemic stromal cells as compared to the 
normal counterpart 
37
, strongly suggesting the involvement of a leukemic ‘niche’ 
signal in leukemic transformation as well as LSC maintenance. 
In this regard, genetic profiling comparing the BM and PB leukemic cells in AML has 
been performed 
38
. Despite of a highly similar gene expression profile, the study 
showed that expression of c-myb, HOXA9, LYN, cystatin C and LTC4s were 
significantly different between BM and PB samples. Nevertheless, the use of the 
heterogenous non-purified mononuclear cell (MNC) fraction for comparison has 
largely limited the interpretation of such data. Hence, definitive evidence is still 
lacking and that the mechanisms whereby regulatory signals are translated to 
impact on LSC in the BM milieu are far to be elucidated.  
 
1.4 Leukemia stem cells in Chronic Myeloid Leukemia (CML) 
 
Philadelphia-positive (Ph+) CML is a myeloproliferative disease characterized by 
granulocytosis and splenomegaly. The disease course is divided into three phases, 
triphasic, starting with a chronic phase, progressing to an accelerated phase, and 
ultimately ending in a terminal phase called blast crisis, which presents clinical and 
features comparable with Acute Leukemia. The Ph chromosome is present  in over 
90% of CML cases, being the diagnostic molecular hallmark of the disease. After the 
introduction, 13 years ago, of selective drugs with tyrosine-kinase inhibitory activity 
on BCR-ABL fusion gene, the prognosis of this haematological malignancies 
dramatically improved both in young and adult patients. Nevertheless, a definitely 
cure for CML is still lacking, due to the apparent and demonstrated persistence, 
even after allogenic stem cell transplantation, of quiescent LSCs 
39
. Although BMT is 
16 
 
considered a “curative” therapy for CML, the cure is apparently “relative” due to the 
existence of residual LSCs.  
From a practical point of view, indeed, in the current clinical management, the BCR-
ABL kinase inhibitor imatinib and many second generation TKIs have been 
developed to treat CML and now serves as the frontline therapy for the patients 
with chronic phase CML. Despite their ability to control CML, these compound do 
not appear to cure the disease, as LSCs evade treatment, as demonstrated in many 
reports 
40
. Moreover, both in vitro and in vivo studies showed that CD34+ cells 
derived from the bone marrow of CML patients could not be effectively killed by 
imatinib treatment. CD34+ CML stem cells, especially the non-dividing CD34+ cell 
population, were not sensitive to imatinib-inhibition in vitro, and this was further 
confirmed by the detection of BCR-ABL mRNA transcripts in CD34+ bone marrow 
cells from CML patients after a long-term treatment with imatinib 
41
. The minimal 
effect of BCR-ABL kinase inhibitor on LSCs was also observed in the CML mouse 
model 
42
. 
The second generation TKI, dasatinib, is a dual BCR-ABL/SRC kinase inhibitor, whit 
demonstrated activity in controlling CML. In CML mouse model, mice treated with 
dasatinib lived significantly longer than those treated with imatinib 
42
. These  data 
correlated with significantly lower numbers of BCR-ABL-expressing leukemic cells in 
peripheral blood compared with placebo- and imatinib-treated mice. However, all 
dasatinib-treated CML mice eventually died of this disease, meaning that, like 
imatinib, this drug is not able to completely eradicate LSCs in CML mice. This 
conclusion on the failure of dasatinib to eradicate LSCs is supported by the 
observation that quiescent human CD34+CD38- CML cells are resistant to dasatinib 
treatment 
43
. So, neither imatinib nor dasatinib are able to completely eradicate 
BCR-ABL-expressing HSCs, suggesting that neither drug alone will cure CML and 
targeting of multiple pathways in LSCs is required to cure the disease. 
17 
 
It is still unclear why imatinib and dasatinib do not completely eradicate LSCs, but 
several reasons should be excluded, based on the data available. First of all, the drug 
can access stem cells, as inhibition of intracellular BCR-ABL phosphorylation by 
dasatinib in the stem cells were detected 
42
, but its activity is not enough to 
eradicate the LSC compartment. Second, the inability of dasatinib to cure CML mice 
is not due to the appearance of mutations (e.g. BCR-ABL-T315I resistant clone) in 
the mice because CML mice treated with dasatinib for about 3 months contained 
>40% of GFP+Gr-1+ cells, among which there were large numbers of LSCs. 
Sequencing analysis of isolated genomic DNA from bone marrow cells of these mice 
did not show the T315I mutation in the BCR-ABL kinase domain
42
. In addition, the 
failure of imatinib to eradicate LSCs is not related to the c-kit function, because both 
imatinib and dasatinib inhibit c-kit 
44
. These results confirm that inhibition of BCR-
ABL kinase activity alone is insufficient to eradicate LSCs 
45
. 
The current challenge, therefore, is to identify the molecular pathways which are 
involved and contribute to the maintenance, survival and self-renewal in CML LSCs, 
in order to discover molecular target potentially to be hit by specific drugs, in 
combination with TKIs. Therefore, as in AML, a real deep and complete cure may 
require complete eradication of these stem cells. 
Thus, since CML patients receiving BMT can relapse LSCs are not eliminated.  
CML is defined as a stem cell disease that results in the clonal expansion of BCR-ABL 
expressing cells, resulting from the t(9;22)(q34;q11.2) balanced translocation. BCR-
ABL rearrangement occurs in a pluripotent hematopoietic stem cell, and LSCs in CML 
could be defined as part of properties of normal HSCs. Various subpopulations of 
CD34+ cells from CML patients have been isolated, and cells in each of the CD34+ 
subpopulations were examined for the presence of BCR-ABL mRNA 
46
, showing that 
BCR-ABL mRNA could be found in CD34+CD38- and CD34+CD38+ cells. Furthermore, 
other colleagues reported that enriched CD34+ cells from patients with CML could 
18 
 
be transplanted into NOD/SCID mice 
47
, although the mice did not develop lethal 
CML-like disease. The failure of BCR-ABL to induce typical CML in NOD/SCID mice 
does not necessarily indicate that this model is not suitable for examining LSCs, as 
human leukemia cells were indeed transplanted and survived in the recipient mice. 
It is obvious that the use of a NOD/SCID strain that allows more efficient 
engraftment of donor cells would likely improve the engraftment of human CML 
cells 
48
. Therefore, a full understanding of the biology of LSCs requires the 
development of a good animal model that allows analysis of CML LSCs in the future. 
 
 
1.4.1 Critical molecular pathways in CML LSCs 
 
BCR-ABL plays a critical role in the maintenance of survival of LSCs, as all critical 
molecular pathways identified so far can be activated by BCR-ABL. It is reasonable to 
think that the stemness of BCR-ABL-expressing HSCs is maintained by a complex 
molecular network involving BCR-ABL and its interaction with other downstream 
signaling pathways. Thus, these pathways would be specifically involved in the 
survival regulation of LSCs but not normal stem cell counterparts. In other words, it 
could be possible to identify genes that play critical role in the regulation of LSC 
function. This idea is supported by the identification of the Alox5 gene as a key 
regulatory gene for LSCs but not normal hematopoietic stem cells. So far, there have 
been no data that do not support a role of BCR-ABL in the maintenance of the 
stemness of LSCs. However, a critical question to ask is why BCR-ABL kinase 
inhibitors such as imatinib and dasatinib are incapable of eradicating LSCs, if BCR-
ABL kinase activity is inhibited? It has been shown that the inhibition of BCR-ABL 
kinase activity by imatinib in LSCs does not completely compromise BCR-ABL 
function 
42
, indicating the kinase-independent function of BCR-ABL.  
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A complete removal of BCR-ABL protein would have a much stronger inhibitory 
effect on LSCs. Besides targeting BCR-ABL, the identification and inhibition of key 
BCR-ABL downstream signaling molecules/pathways will offer effective therapeutic 
strategies aiming to eradicate LSCs. Below are some examples of the key pathways 
activated by BCR-ABL in LSCs (Figure 5, 6). 
 
                       
Figure 5 Critical molecular pathways in LSCs 
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Figure 6 Cell-surface markers and therapeutic targets of myeloid leukemia stem cells.  
Potential agents and strategies for the eradication of LSCs are depicted in red and include 
antibodies and fusion proteins as well as small-molecule inhibitors. (Adapted from Daniela S. 
Krause and Richard A. Van Etten Right on target: eradicating leukemic stem cells, TRENDS in 
Molecular Medicine Vol.13 No.11)  
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1.5 Hedgehog pathway 
 
Many emerging laboratory and clinical investigations, in the recent years, have 
shown that Hedgehog signaling (Hh) represents a novel therapeutic target in various 
human cancers 
49,50
. It’s a signaling pathways which physiologically regulates self-
renewal and terminal differentiation during the embryonic development, becoming 
typically silenced after birth, in adult tissues.  Its reactivation, infact, usually may 
appear only during tissue repair 
51
.  
Interestingly, aberrant Hh pathway signaling has been implicated in the 
pathogenesis, self-renewal, and chemotherapy resistance of a growing number of 
both  solid and hematologic malignancies, defining a potential target not only for 
preclinical studies but also for identification of new tailored therapies. 
Major components of the Hh pathway, which will be further described in details, 
include the Hh ligands (Sonic, Desert, and Indian), the transmembrane receptor 
Patched, the signal transducer Smoothened (Smo), and transcription factors Gli1–3 
which regulate the transcription of Hh target genes. Mutations in Hh pathway 
genes, as expected, increased Hh signaling in tumor stroma, and Hh overexpression 
in self-renewing cells (cancer stem cells) have been described. These different 
modes of Hh signaling, therefore, have implications for the design of Hh pathway 
inhibitors and their integration into conventional treatment regimens. 
The presence of a naturally-occurring Smo inhibitor, cyclopamine, has encouraged 
the development of several derivative compounds, which are currently objectives of 
clinical trials. Relevant and interesting encouraging laboratory and in vivo data has 
resulted in Phase I and II clinical trials of Smo inhibitors, but the optimal 
combination and sequence of these targeted therapies into current treatment 
algorithm still remain a challenge.  
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1.5.1 The pathway description 
 
The Hh signaling pathway is activated by the binding of Hh ligand to the 
transmembrane receptor, Patched (Ptc).  In the absence of ligand, Ptc suppresses 
the Hh signaling cascade by inhibiting the activity of a second transmembrane 
protein, SMO.  Binding of Hh ligand to Ptc alleviates repression of SMO, allowing 
SMO to transduce the signal to the cytoplasm resulting in activation of zinc finger 
transcription factor, Gli.  Gli translocates into the nucleus and activates transcription 
of target genes including additional Gli family members and Ptc (Figure 7). 
 
 
 
 
Figure 7 Proposed mechanism for Hedgehog (Hh) pathway activation. In the absence of Hh 
ligands, Gli2 and Gli3 (Glis) form a protein complex with other proteins, and the suppressor of 
Fused (SUFU). Furthermore, Patched (Ptch) suppresses the signaling activity of Smo. Costal2 might 
promote the degradation or proteolysis of Glis, which generates the repressor form of Glis (Rep-
Gli2 ⁄ 3). The translocaTon of Rep-Gli2 ⁄ 3 to the nucleus inhibits the transcripTon of target genes, 
including Gli1 and Ptch, and cancer proliferation- and invasion-related genes (left panel). In the 
presence of Hh, it binds to Ptch, activating Smo, and both degradation of Gli2 and proteolytic 
processing of Gli3 into its repressive form are inhibited, thereby permitting Gli2 to function as a 
strong activator of Hh signaling (Act-Gli2) and allowing full-length Gli3 to serve as an activator 
(Act-Gli3) (right panel). (Modified from Onishi H, Katano M: Hedgehog signaling pathway as a 
therapeutic target in various types of cancerCancer Sci. 2011 Oct;102(10):1756-60) 
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The Hh signaling pathway is essential for multiple functions in embryonic 
development, and is therefore considered a key developmental pathway.  
Disruption of this crucial pathway during human development results in severe birth 
defects represented by holoprosencephaly, polydactyly, cranial defects, and skeletal 
malformations
52
.  Aberrant activation of the Hh pathway has also been implicated in 
a lot of human malignancies, and can occur by two mechanisms, both of which 
result in cancer.   
First, mutations in Ptc or SMO genes result in constitutive activation of the pathway 
and upregulation of Gli.  Mutations in Hh signaling members have been reported in 
basal cell carcinoma, medulloblastoma, and rhabdomyosarcoma 
53, 54
. Moreover, a 
direct link between mutation driven aberrant Hh signaling and human tumorgenesis 
is found in Gorlin Syndrome, characterized by the development of multiple basal cell 
carcinomas (BCC) and a predisposition to medulloblastoma and rhabdomyosarcoma. 
These patients present a germline inactivating mutation in the repressor Ptc which 
results in constitutively active SMO and upregulation of Hh target genes.  The link 
between mutations in Ptc and BCC was also reported in a majority of sporadic BCC 
tumors 
53, 54
.  A significant number of sporadic medulloblastomas, a pediatric cancer 
of the cerebellar granule neuron progenitor cells, can also be attributed to 
inactivating mutations in Ptc gene 
54
.   
The second method of Hh activation is through autocrine or paracrine mechanisms 
of ligand driven Hh pathway activation in adult tissues with a normally dormant Hh 
pathway. In some cancers Hh pathway members are expressed in the tumor cells 
and directly affect the growth of the tumor, resulting in an autocrine positive 
feedback loop. In other cases, Hh ligand produced by tumor cells may activate the 
pathway in adjacent stroma, leading to the release of growth factors that support 
tumor growth or angiogenesis as part of the tumor microenvironment 
55
 (Figure 8).  
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Figure 8 HH pathway regulation in cancer (Adapted from Scales S. et al, Trends Pharmacol.Sci., 
2009) 
 
This has been reported in pancreatic, breast, prostate, small cell lung cancer and 
more recently in hematopoietic malignancies 
56,
 
57,
 
58, 59,60,
 
61
 (Figure 9). 
 
 
25 
 
 
 
Figure 9 A schematic presentation of the different modes of aberrant HH signaling and the 
subsequent different types of cancers which can be categorized on the basis of at which stage the 
HH signaling inﬂuences the neoplastic progression (Adapted from Swayamsiddha Kar, Moonmoon 
Deb et al., Intricacies of hedgehog signaling pathways: A perspective in tumorigenesis, 
Experimental Cell Research 318 (2012) 1959–1972). 
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1.5.2 Role of Hedgehog pathway in Hematologic Malignancies 
 
As previously assessed, the identification of cancer stem cells that self-renew, 
reinitiate tumor development and give rise to the neoplastic bulk, represented a 
milestone in the understanding of leukemia pathogenesis. Ultimately, this biological 
capacity can contribute to resistance and metastatic spread, affecting, at the end, 
overall survival. Standard chemotherapy, radiotherapies and some targeted 
therapies, as widely demonstrated, can greatly reduce tumor bulk but may be less 
effective on quiescent cancer stem cells. The key challenge has been, therefore, in 
identifying the molecular mechanisms that maintain and support cancer stem cell 
self-renewal and survival, in order to hit the initiating cell, responsible for tumor 
appearance. 
In Ph+ CML subset, it has been widely demonstrated the ability of leukemic BCR-ABL 
clone to escape from direct tyrosine kinase inhibition, induced by first and second 
generation TKIs. For this reason, stem cell transplantation (with its high morbidity 
and mortality rates) remains the only potential cure for the relatively few patients 
with this option. Thus, the identification of less toxic and potentially curative 
therapies which target this disease remains of great interest. Several studies 
60, 61
 
have identified components of the Hh pathway as potential drug targets in BCR-ABL-
positive CML as it may play a key role in leukemic stem cells (LSC’s). Dierks et al 
described a 4-fold induction of Gli1 and Ptc1 in CD34+ chronic or blast crisis CML 
cells. BCR-ABL expression induced SMO, Gli1 and Ptc levels within the stem cell 
compartment in a mouse model of CML. The Ptc1 expression level is 20-fold higher 
in patient derived CD34+ blast-crisis CML cells compared to CD34+ chronic-phase 
CML cells 
62
. Gli2 expression increases progressively in chronic phase and blast crisis 
CML samples, and SMO is essential for expansion of the leukemic stem cell pool as 
compared to normal hematopoietic stem cells (HSC’s). Zhao et al demonstrated that 
Hh signaling is activated in LSCs through up regulation of SMO. While SMO does not 
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impact long-term reconstitution of regular hematopoiesis, the development of 
retransplantable BCR-ABL-positive leukemia was abolished in the absence of SMO 
expression. Furthermore, loss of SMO impairs HSC renewal and decreases induction 
of CML by the BCR–ABL oncoprotein and by depletion of the CML stem cell, whereas 
constitutively active SMO augments CML stem cell number to accelerate disease. 
The cell fate determinant Numb, which depletes CML stem cells, is increased in the 
absence of SMO activity. Pharmacological inhibition of Hh signaling impairs not only 
the propagation of CML driven by wild-type BCR–ABL, but also the growth of 
Imatinib-resistant mouse and human CML by reducing the number of LSCs in vivo 
61
. 
Finally, SMO was significantly upregulated in CML patients, suggesting activation of 
the Hh pathway may be associated with CML progression
63
. Collectively, these data 
indicate that Hh pathway activity is required for maintenance of normal and 
leukemic stem cell populations in CML, and raise the possibility that drug resistance 
and disease progression associated with TKI failure might be avoided by targeting 
this essential stem cell maintenance pathway. 
In addition to CML, aberrant Hh signaling has been described in a variety of human 
leukemia and leukemia stem cells. Expression levels of Ptc, SMO and Gli1 were 
examined in several leukemic cell lines 
64
. Ptc and SMO were expressed in Jurkat T-
ALL cells, and Shh and Gli1 were expressed in human promyelocytic leukemia (HL-
60) and KG-1 cells. Hh signaling is up-regulated in several subtypes of human AML 
cells, including primary CD34+ leukemic cells and cytokine-responsive CD34+ cell 
lines such as Kasumi-1, Kasumi- 3 and TF-1. These CD34+ cells express Gli1 and Gli2, 
indicative of active Hh signaling. Inhibition of Hh signalling induced apoptosis after 
48 h of exposure, although these CD34+ cell lines exhibited resistance to cytarabine 
(Ara-C). This data was confirmed by reverse transcription– polymerase chain 
reaction (RT-PCR) for Hh pathway components and a Gli-responsive reporter assay 
65
. 
Finally, upregulation of Hh pathway components has been observed in 
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chemoresistant AML cell lines in vitro, and pharmacological inhibition of the Hh 
pathway resulted in decreased multi-drug resistance (MDR-1) or P-glycoprotein 
(Pgp) expression in these cells 
66
. Given the central role that Hh signalling plays in 
cell differentiation, Hh inhibition represents a mechanistically novel approach to 
eliminate the LSC population and thus abrogate tumor proliferation in at least a 
subset of CD34+ myeloid driven hematapoietic malignancies. 
Additional evidence for the importance of Hh in leukemia’s is derived from patients 
enrolled in a recently closed single agent hematology trial with a Smo-inhibitor 
molecule, which will be the object of this research activity. The results will be 
showed in the related chapter.  
 
 
1.6 New Smo-inhibitor drugs in clinical development  
 
 
After the identification of a natural Hh pathway antagonist, represented by 
Cyclopamine, many synthetic and semi-synthetic derivatives, with increased potency 
and bioavailability have been introduced in clinical research, both in hematological 
malignancies and in solid tumors.  
Among these, in Table 2 are reported the most promising compounds, currently 
objectives of company sponsored experimental clinical trials.  
All these molecules act at the level of Smo, after oral administration, according to 
different schedules. As expected, similar to challenges underlined in other 
neoplastic malignancies, an open question about the potential benefit and the most 
appropriate combination chemotherapy approach, currently hasn’t led to any 
answer.    
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Drug (Sponsor) Indications Phases 
GDC-0449 (Genentech) Advanced solid tumors, BCC, breast, 
chondrosarcoma, colorectal, gastric,   
Phase II  
LDE-225 (Novartis) Advanced solid tumors, BCC, chronic myeloid 
leukemia, pancreatic  
Phase I, II  
BMS-833923 (Bristol-Myers Squibb) Advanced solid tumors, BCC, chronic myeloid 
leukemia, esophageal,   
Phase I, II  
XL139 (Exelixis) gastric, multiple myeloma, small cell lung   
IPI-926 (Infinity) Advanced solid tumors, chondrosarcoma, head and 
neck, myelofbrosis, pancreatic 
Phase I, II  
SMO-INHIBITOR (Pfizer) Advanced solid tumors, hematologic malignancies  Phase I  
LEQ-506 (Novartis) Advanced solid tumors  Phase I  
TAK-441 (Millenium) Advanced solid tumors  Phase I  
Itraconazole BCC, metastatic prostate cancer, non-small cell lung 
cancer 
Phase II 
 
Table 2 Smoothened inhibitors currently in clinical trials for cancer (Modified from Lin TL, Matsui 
W. Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets 
Ther. 2012;5:47-58.  
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1.7 A new Smo-inhibitor: molecular and PK features 
 
The hereby described Smo inhibitor compound is a potent and selective inhibitor of 
Hedgehog (Hh) signaling in vitro, and has showed significant antitumor efficacy in 
vivo. The first experience in a mouse model of Hh pathway-driven tumor has been 
performed in medulloblastoma setting, demonstrating that the drug inhibits 
pathway activation (Gli1 expression) and produces rapid and complete tumor 
regression. Moreover, the compound was studied in haematological malignancies, 
demonstrating its capability of reducing leukemic burden in a blast crisis chronic 
myeloid leukemia mouse model, and of inhibiting tumor formation in secondary 
recipients. 
Preclinical pharmacokinetic/ pharmacodynamic (PK/PD) modelling suggests a target 
human dose of 15 mg/day, projected to yield at least 50% of tumor Gli1 mRNA 
inhibition from baseline levels. A 15 mg dose is projected to result in a Cmin 
(minimum plasma concentration) of 62 ng/mL total (5.6 ng/mL free) and a Cav 
(Average drug concentration) of 79 ng/mL total (7.2 ng/mL free). The anticipated 
maximum dose in the clinic is 200 mg/day which is projected to result in a Cmax 
(maximum plasma concentration) of 2150 ng/mL total (196 ng/mL free) and a Cave 
of 967 ng/mL total (88 ng/mL free). 
Absolute oral bioavailability of the molecule following single dose oral 
administration was 33% in rats and 68% in dogs. Plasma protein binding of the drug  
in mouse, rat, dog, and human plasma ranged from 85% to 93%. A volume of 
distribution at steady state (Vss) of 4.78 and 4.21 L/kg was observed in rats and dogs, 
respectively. Hepatic metabolism is predicted to be the major clearance pathway for 
the drug in humans. Its in vitro metabolism  was consistent across preclinical species 
and humans. 
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1.7.1 Drug Metabolism  
 
This Smo-inhibitor appeared to be metabolized to several oxidative metabolites. 
Preliminary assessment using individual recombinant P450 enzymes suggests that 
CYP3A4 plays a major role in mediating the metabolism of the drug. All metabolites 
observed in human in vitro incubations were present in one or more of the 
evaluated preclinical species. In vitro, the molecule did not inhibit CYP1A2, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 30 μM. Based on in 
vitro and in vivo evaluations of the drug, systemic plasma clearance, volume of 
distribution at steady state, elimination half-life and oral bioavailability in humans 
are projected to be 1.03 mL/min/kg, 2.7 L/kg, 30 hours and 55%, respectively. 
The compound was evaluated in rat and dog repeat-dose toxicity studies up to 1 
month in duration. The Smo-inhibitor compound was well tolerated up to 50 
mg/kg/day in the rat and 5 mg/kg/day in the dog. In both the rat and the dog, a 
greater than proportional increase in exposure occurred with increasing dose. In the 
1-month rat study, the increase in mean AUC(0-24) values were approximately 175-
fold and 232-fold greater than the dose (50-fold) range evaluated for Day 1 and Day 
29, respectively. In the 1-month dog toxicity study, the mean AUC(0-24) values were 
approximately 165-fold (male) and 360-fold (female) greater than the dose (30-fold) 
range evaluated on Day 1. Deaths and/or moribund euthanasia occurred in the 7-
day and 10-day rat studies, and the 1-month dog study at 250, 500 or 30/15 
mg/kg/day, respectively. Cause of death/morbidity in both species was attributed to 
kidney toxicity. The target organ in the rat 1-month toxicity study included kidney 
(tubular degeneration/necrosis, cytomegaly, inflammation, regeneration) and bone 
(decreased/disorganized chondrocytes in epiphysis); the no observed adverse effect 
level (NOAEL) was 10 mg/kg/day (less than the projected human Cave at steady 
state at a 200 mg dose). The kidney changes showed some signs of reversibility but 
did not entirely reverse, while the bone changes persisted. 
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The target organ in the 1-month toxicity study in the dog was limited to the kidney 
(tubular necrosis, granular/mineralized casts, dilated tubules); the NOAEL was 1 
mg/kg/day which is less than the projected human Cave at steady state at a 200 mg 
dose. Mild changes in the kidney were observed at 5 mg/kg/day which are also 
below the projected Cave at a 200 mg dose. The kidney changes in the dog were 
completely reversed in males and partially reversed in females after a 6-week 
reversal period. 
In the acute central nervous system (CNS) and respiratory studies in the rat, no 
effects were observed at the high dose of 50 mg/kg. The maximum plasma 
concentration at 50 mg/kg (group mean free Cmax of 617 ng/mL) from the 1-month 
rat study is 3-fold above the projected human free Cmax concentration of 196 
ng/mL at a 200 mg dose. Increases in QT and QTc were noted. The Smo inhibitor 
compound was negative in the definitive in vitro bacterial mutagenicity assay, 
human lymphocyte assay and the in vivo rat micronucleus. The molar extinction 
coefficient for the Smo inhibitor compound at 290 nm is 9622 L/mol/cm; therefore, 
the Smo-inhibitor compound has the potential to be phototoxic. 
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2. AIMS OF THE STUDY 
 
The role of Hedgehog pathway in LSCs maintenance and self renewal both in AML 
and CML have been demonstrated by in vitro and in vivo studies. 
In clinical development, data concerning hematological malignancies are still lacking.   
The aims of this study have included both preclinical and clinical activities, in order 
to: 
1. Conduce a first in man Phase I clinical trial in patients with hematological 
malignancies, based on the administration, as a single agent, of a new Smo- 
inhibitor drug, aimed to assess:  
a. the safety and tolerability profile of the compound 
b. the maximum tolerated dose (MTD1) of the compound  
c. the pharmacodynamics  and the pharmacokinetics of the compound  
d. the clinical and the hematological response observed in treated patients  
2. Identify useful biomarkers related to Hh pathway in order to detect stem cell 
persistence in myeloid hematological malignancies 
3. Evaluate GEP of CD34+ cells before and after treatment with Smo-inhibitor 
drugs 
4. Evaluate the rationale for combination schedules of Smo-inhibitor with TKIs in 
Ph+ Leukemias, according to innovative phase I/II clinical trials.  
5. HH pathway contribution to functional human LSC propagation  
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3. MATERIALS AND METHODS 
 
3.1 First in man, Phase I Multi-Center Clinical Trial 
 
The above described innovative Smo-inhibitor drug has been tested in an open-
label, multi-center, Phase 1 study. The compound was administered orally as single 
agent to adults with select advanced hematologic malignancies (Phase 1a), after the 
obtainment of a signed informed consent. A second part (Phase 1b), consisting in 
the combination treatment with dasatinib or bosutinib for CML patients in AP/BC 
was planned, but has not been performed yet. The protocol, therefore, was 
designed for previously strongly treated patients with relapsed or refractory 
advanced hematological malignancies, such as AML, CML, MDS or PMF. 
Phase 1a was aimed to assess the above mentioned Smo-inhibitor administered as 
single agent once daily in a continuous regimen. A dose escalation design was 
applied in 3-6 patient cohorts up to identification of the maximum tolerated dose 
(MTD1). The starting dose was 5 mg once daily. A lead-in period on Day -6 for each 
dose escalation cohort was planned, in which the single-dose pharmacokinetics and 
pharmacodynamics of the compound was characterized prior to initiation of 
continuous dosing in the first cycle of treatment. The lead-in period duration, PK 
time-points, doses and/or regimens used in subsequent cohorts could be modified 
based on the exposure (AUC) observed during the lead-in period (although the 
number of PK samples will not be increased). 
Once the MTD1 is established, the cohort will be expanded with at least 8 additional 
patients to further characterize safety and tolerability at the MTD1 and to collect 
blood and urine for metabolite profiling/urine PK. 
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Phase 1b will assess the drug in combination with dasatinib or bosutinib as two 
separate arms, both combinations administered orally once daily with food in a 
continuous regimen to patients with AP/BC CML.   
Treatment with the compound single agent or in combination with dasatinib or 
bosutinib (Phase 1a and 1b, respectively) could continue for up to 1 year (52 weeks) 
or until disease progression, patient withdrawal or unacceptable toxicity occurs.  
Patients who complete treatment for 1 year (52 weeks) will be considered to have 
completed the trial.  Patients who are still on trial at 1 year and who continue to 
benefit from treatment may have the option to continue treatment upon agreement 
between the investigator and sponsor, and pending study drug availability. 
Pre- and post- Smo inhibitor dose blood, bone marrow and normal skin was 
obtained for biomarker assessments and evaluating potential genetic changes that 
could correlate to clinical outcome.  These assessments included pharmacodynamic 
analyses of Hedgehog target genes and other signaling pathways which may interact 
with the Hedgehog pathway. 
 
Figure 10 Treatment schedule of cycle 1 
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3.1.1 Statistical Methods: Sample Size Determination 
 
The number of patients to be enrolled in the study depended on the observed safety 
profile, and the number of dose escalations in the two phases of the study. 
The expected number of patients for Phase 1a was estimated to be 42. 
 
3.1.2  Rationale for Selection of the Starting Dose 
 
The starting dose for the Smo inhibitor compound in this first-in-patient trial in 
cancer patients has been determined to be 5 mg daily, based on information derived 
from the 1-month repeat dose toxicology studies in rats and dogs (Data coming from 
Investigators’ Brochure). 
The doses tested in the 1-month toxicology study in the rat were 1, 10, and 50 
mg/kg/day orally, and in the 1-month dog study were 1, 5, and 30/15 mg/kg/day 
orally. 
According to DeGeorge et al (1998) , the currently accepted algorithm for calculating 
a starting dose in clinical trials for cytotoxic agents is to use one-tenth of the dose 
that causes severe toxicity (or death) in 10% of the rodents (STD10) on a mg/m  
basis, provided this starting dose does not cause serious, irreversible toxicity in a 
non-rodent species.  If irreversible toxicities are produced at the proposed starting 
dose in non-rodents or if the non-rodent is known to be the more sensitive animal 
model, then the starting dose would generally be one-sixth of the highest dose 
tested in the non-rodent that does not cause severe, irreversible toxicity.  The 
human equivalent starting dose was calculated to be ~ 55 mg based on the rat 
STD10, and ~6 mg based on the NOAEL of 1 mg/kg in the dog. 
Because the dog was determined to be the more sensitive species, the starting dose 
of the compound  was 5 mg and used as the starting dose for the FIP study. 
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3.1.3 Inclusion Criteria 
 
Patient eligibility was reviewed and documented by an appropriately qualified 
member of the investigator’s study team before patients are included in the study. 
Patients enrolled had to meet all of the following inclusion criteria to be eligible for 
enrollment into the study: 
1. Phase 1a: Patients with select advanced hematologic malignancies who are 
refractory, resistant or intolerant to prior therapies.  They may be newly diagnosed 
(patients with AML must be in compliance with national treatment guidelines, see 
below) and previously untreated (for all diseases with the exception of non-T315I 
CML (see below)), but not eligible for standard treatment options, or for whom 
standard therapies are not anticipated to result in a durable response. Eligible 
patients are limited to 1. Myelodysplastic Syndrome (any MDS International 
Prognostic Scoring System or IPSS score), 2. Myleofibrosis, 3. Chronic 
Myelomonocytic Leukemia (CMML), 4. CML T315I mutants (may be previously 
untreated), 5. non-T315I CML (any phase; must have received at least one prior 
treatment), 6. Acute Myeloid Leukemia (AML; not eligible to receive standard 
therapy based on national treatment guidelines [Morra et al, 2008;  NCCN 
guidelines, AML 2010 ). 
Patients with CML: 
 Must have a  confirmed diagnosis as evidenced by the presence of the BCR-
ABL translocation [t(9;22)] by fluorescence in situ hybridization (FISH), 
cytogenetics, or quantitative polymerase chain reaction (QPCR) for chronic 
myeloid leukemia in either chronic, accelerated or blast phase. 
 Non-T315I CML must have received at least one prior therapy. 
 May be resistant or intolerant as defined by: 
a. In CML-CP, primary resistance is defined as failure to achieve a complete 
hematologic response (CHR) following 3 months on therapy; failure to achieveany 
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cytogenetic response (CyR) following 6 months on therapy, failure to achieve a 
major cytogenetic response following 12 months on therapy, or failure to achieve a 
complete cytogenetic response following 18 months on therapy. 
b. Secondary resistance is defined as a loss of CHR (defined by leukocytosis 
confirmed with at least one WBC>15K not felt to be due to a secondary cause); loss 
of a MCyR (defined by ≥30% increase in the number of metaphases); or disease 
progression to AP or BP. 
c. In CML-AP or CML-BC, resistance is defined as the failure to achieve a hematologic 
response, an increasing WBC, or an overt disease progression. 
d. Intolerance for all phases is defined as discontinuation of prior therapy due to 
adverse events at the lowest approved dose or if a patient can only tolerate prior 
therapy at less than the lowest approved dose. 
In addition, for all phases (except patients with T315I mutations), patients are 
eligible in the case of unsatisfactory clinical response to the initial course of TKI, but 
who do not meet the definition for refractory, resistant or intolerant (eg, a CML CP 
patient who rapidly progresses on primary therapy, but does not meet the criteria 
for primary resistance because they have not been on TKI for 3 months; or patients 
with co-morbid diseases who cannot tolerate TKI therapy). 
 
3.1.4 Exclusion Criteria 
 
Patients presenting with any of the following were not be included in the study: 
1. Patient has undergone a donor lymphocyte infusion (DLI) in the prior 30-days; 
2. Patient is known to be refractory to platelet or packed red cell transfusions per 
Institutional Guidelines; 
3. Patient with active malignancy with the exception of basal cell carcinoma, non-
melanoma skin cancer, carcinoma-in-situ cervical or skin cancer. Other concurrent 
malignancies will be considered on a case-by case basis; 
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4. Any one of the following currently or in the previous 6 months: myocardial 
infarction, congenital long QT syndrome, torsades de points, arrhythmias (including 
sustained ventricular tachyarrhythmia and ventricular fibrillation), right bundle 
branch block and left anterior hemiblock (bifascicular block), unstable angina, 
coronary/peripheral artery bypass graft, symptomatic congestive heart failure (CHF 
NY Heart Association class III or IV), cerebrovascular accident, transient ischemic 
attack or symptomatic pulmonary embolism; 
For Phase 1a: QTc interval of >470 msec and for Phase 1b: QTc interval of >450 
msec; 
7. Bradycardia defined as HR <50 bpm; 
8.For Phase 1b: Uncorrected serum calcium, potassium, magnesium or phosphate 
below institutional LLN; 
9. Patient with an active, life threatening or clinically significant uncontrolled 
systemic infection; 
10. Patients with active central nervous system (CNS) involvement by leukemia. 
Patients with prior history of CNS disease will qualify if active disease is ruled out by 
imaging studies or spinal tap; 
11. Active graft versus host disease other than Grade 1 skin involvement; 
12. Patients taking immunosuppressants for GVHD (including but not limited to: 
steroids, cyclosporine, tacrolimus, methotrexate or mycophenolate mofetil) from 
14-days prior to the first dose of TKI until study treatment discontinuation; 
13. Known human immunodeficiency virus (HIV) or acquired immunodeficiency 
syndrome (AIDS)-related illness or with active Hepatitis B or C infection; 
14. Known malabsorption syndrome or other condition that may impair absorption 
of study medication (eg, gastrectomy or lap band); 
15. Prior or concurrent anti-cancer treatment with a Hedgehog inhibitor or 
concurrent treatment with other investigational (excluding bosutinib) or approved 
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oncology agents. Prior treatment with SMO-INHIBITOR is acceptable for inclusion in 
Phase 1b if the patient is withdrawn from the Phase 1a portion of the study for 
disease progression, meets Phase 1b inclusion criteria, has tolerated SMO-
INHIBITOR as a single agent and following sponsor approval; 
16. Concurrent administration of herbal preparations; 
17. Current use or anticipated need for food or drugs that are known 
strong/moderate CYP3A4 inhibitors, including their administration within 7-days 
prior to the first compound/TKI dose (ie, grapefruit juice, ketoconazole, 
itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, indinavir, 
saquinavir, ritonavir, nelfinavir, nefazodone, lopinavir,  troleandomycin, mibefradil, 
conivaptan, erythromycin,  azithromycin, verapamil, atazanavir, fluconazole, 
darunavir, diltiazem, delavirdine, aprepitant, imatinib, tofisopam, ciprofloxacin and 
cimetadine); 
18. Current use or anticipated need for drugs that are known strong CYP3A4 
inducers, including their administration within 7-days prior to the first drug/TKI dose 
(ie, phenobarbital, rifampin, phenytoin, carbamazepine, rifabutin, rifapentin, St. 
John’s Wort); 
19. Current use or anticipated need of drugs that are P-gp inhibitors (cyclosporine, 
tacrolimus, ritonavir, verapamil, erythromycin, ketoconazole, itraconazole, 
quinidine, elacridar and valspodar) or P-gp inducers (rifampin and St. John’s Wort), 
including their administration within 7-days prior to the first SMO-INHIBITOR/TKI 
dose; 
20. Current use or anticipated need for drugs that are CYP3A4 substrates and have a 
narrow therapeutic index, including their administration within 7-days prior to the 
first drug/TKI dose (eg, cyclosporine, sirolimus, astemizole, terfenadine, cisapride, 
pimozide, quinidine or ergot alkaloids); 
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21. Chronic systemic corticosteroid treatment, although topical applications, inhaled 
sprays, eye drops, local injections of corticosteroids and systemic steroids required 
for acute medical interventions are allowed; 
22. Current non-prescription drug or alcohol dependence; 
23. For Phase 1b only: Concurrent use of aspirin, clopidrogrel, dipyridamole, 
ticlopidine or other platelet inhibitors; 
24. Pregnancy or breastfeeding.  Female patients must be surgically sterile or be 
postmenopausal, or must agree to the use of effective contraception during the 
period of therapy. All female patients with reproductive potential must have a 
negative 
pregnancy test (serum or urine) prior to enrollment. Male patients must be 
surgically sterile or must agree to use effective contraception during the period of 
therapy; 
25. Other severe acute or chronic medical or psychiatric condition or laboratory 
abnormality that may increase the risk associated with study participation or study 
drug administration, or may interfere with the interpretation of study results, or in 
the judgment of the investigator would make the patient inappropriate for entry 
into the study. 
3.1.5 Study drug formulation 
 
The drug is formulated in tablets containing 5 mg, 10 mg, 25 mg and 100 mg of 
study medication.  The tablets are packaged in High-density polyethylene (HDPE) 
bottles, with protection from moisture.  
3.1.6 Laboratory Safety Assessments 
 
According to the clinical trial, laboratory values were checked at defined time 
points. These parameters involved, blood chemistry, coagulation tests, hematology. 
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In details: White blood cell count plus differential (including neutrophils, 
lymphocytes, eosinophils, basophils, monocytes), platelet count, hemoglobin, 
sodium, potassium, chloride, blood urea nitrogen, creatinine, glucose, uric acid, 
calcium, phosphorus, magnesium, total protein, albumin, total bilirubin, direct and 
indirect bilirubin, aspartate transaminase, alanine transaminase, alkaline 
phosphatase, lactate dehydrogenase, international normalized ratio, prothrombin 
time, and partial thromboplastin time. Microscopic urinalysis: pH, specific gravity, 
protein, glucose, ketones, red and white blood cells, leukocyte esterase, casts, 
crystals and nitrite.  If the urinary protein is ≥2+, then a 24-hour urine is required for 
quantitative measurements of protein, creatinine and glucose. 
Pregnancy test: Serum or urine pregnancy test for women of childbearing potential. 
 
3.1.7 Other Safety Assessments: ECG 
 
Triplicate 12-lead (with a 10-second rhythm strip) tracing in the supine position 
were performed for all ECGs, to determine the mean QTc interval. If any patient had 
a mean pre-or post dose QTc value >480 msec (using both Fridericia and Bazett 
correction methods), immediate correction for reversible causes (including 
electrolyte abnormalities, hypoxia and concomitant medications for drugs with the 
potential to prolong the QTc interval) should be performed. 
 
3.2 Blood for PK Analysis 
 
Blood samples (2 mL whole blood sufficient to provide a minimum of 1 mL of 
plasma) were collected for PK analysis of the Smo-inhibitor for all cohorts as 
outlined in the Schedule of 
43 
 
Activities: during the lead-in period on Day (-6), in Cycle 1 on Day 1, Day 5, Day 8, 
Day 15 and Day 21.  For cycles 2 and above a PK samples were also collected on Day 
1 and Day 15 matched with the ECGs as well as at End of Treatment.  
 
3.2.1 Urine for Analysis of Smo inhibitor and Metabolite Profiling 
 
Urine samples were collected in all cohorts in Phase 1a, on Cycle 1/Day 21 over 0-24 
hours post Smo-inhibitor dosing. 
At the end of the urine collection period, the total volume of urine was measured 
and total volume recorded in the CRF.  The urine were then mixed thoroughly and a 
20-mL aliquot were withdrawn for PK analysis and a further 20-ml aliquot 
withdrawn for metabolite profiling (if there is insufficient urine collected, the urine 
volume apportioned for PK analysis will be prioritized as first). The samples were 
then frozen at -20°C.  
 
3.2.2 Pharmacodynamic Biomarker Assessments 
 
Pharmacodynamic biomarker assessments were performed in patients enrolled in 
the Phase 1a. These assessments included evaluation of the effects of single agent 
Smo-inhibitor alone on Hh pathway related genes.  
Blood samples (~10 mL) were collected for pharmacodynamic biomarker 
assessments during screening, the lead-in period on Day (-6), Cycle 1/Day 8, Cycle 
1/Day 21 and at End of Treatment.  Bone marrow was collected at screening, on Day 
1 of every even cycle, End of Treatment and at investigators discretion for the AML 
and CML AP/BC patients.  For all other patients the bone marrow was collected at 
screening, Day 1 of Cycle 2, 6, 10, End of Treatment and at investigators discretion.   
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3.3 Efficacy Assessments 
 
The study has enrolled patients with select hematologic diagnoses, each having 
specific clinical response criteria.  The response criteria for CML are derived from 
Faderl et al 
67
(1999)  and Cohen et al (2005) 
68
. CMML/MDS, MF, Ph+ ALL and AML 
are derived and defined by the disease specific International Working Groups and 
World Health Organizations (WHO) Guidelines. 
 
 
3.4 Real Time PCR or quantitative PCR with Taqman probes  
 
The gene expression profiling has been quantified through a Real-Time PCR method 
and by the use of Taqman, selective for the following genes: Smo, Gli1, Gli2, Gli3, 
Abcb1, Abcg2 (Applied Biosystems). Moreover, it was necessary to have a reference 
gene, with a stable expression. The most suitable gene for this aim is the one 
codifying for GAPDH. The amplification has been performed loading every sample, in 
double, on a plate consisting in 96 wells (MicroAmp Optical 96-well reaction plate, 
Applied Biosystems), with a whole reaction volume of 25 mcl. The Real-Time PCR 
has been performed on a tool ABI prism 7300 SDS (Applied Biosystems) using these 
amplification procedures: 50°C 2 minutes, 95°C 10 minutes, followed by 40 cycles at 
95°C for 15 seconds and 60°C for 1 minute. The quantitative analysis has been 
performed through ∆∆Ct. 
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4. RESULTS 
 
4.1 Clinical Trial  
 
This first-in-patient Phase 1a dose-escalation study 
69
 was aimed designed to assess 
the dose-limiting toxicities (DLTs) and the recommended Phase 2 dose (RP2D) of the 
above mentioned Smo inhibitor compound, in patients with select hematologic 
malignancies (primary endpoint). Secondary endpoints included safety, 
pharmacokinetics (PK), pharmacodynamics, and preliminary signs of efficacy as 
defined by disease-specific guidelines. Patients had refractory, resistant, or 
intolerant select hematologic malignancies and could be previously untreated but 
not candidates for standard therapies: CML including T315I mutations (any phase), 
acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myelofibrosis 
(MF), or chronic myelomonocytic leukemia (CMML). Cohorts of  3 patients received 
the drug alone, administered continuously in 28-day cycles, starting at a dose of 5 
mg orally once daily.  
Thirty-five patients have been enrolled at doses up to 400 mg: 21 males/14 females; 
AML, 20; MF, 6; CML, 5; MDS, 3; CMML 1, with a median age of 69 (35–79) years. 
ECOG PS was 0/1/2: n=11/16/5 (Table 3). 
The majority of the patients, according to inclusion and exclusion criteria, presented 
with strongly pretreated high risk hematological malignancies, refractory to 
standard chemotherapy or resistant to standard therapeutic approaches.  Clinical 
general conditions of the patients were in line with the advanced status disease.  
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About one half of the entire enrolled population was affected by AML, and the risk 
stratification of these patients is reported in Table 4, according to cytogenetics. 
 
 
Characteristic (N = 35) 
Age, median (range) 69 (35-79) 
Gender, n (%) 
   Female 
   Male 
 
14 (40) 
21 (60) 
ECOG, n (%) 
   0 
   1 
   2 
 
12 (34) 
18 (51) 
5 (14) 
Malignancy, n (%) 
   AML 
   CML 
   CMML 
   MDS 
   MF 
 
20 (57) 
5 (14) 
1 (3) 
3 (9) 
6 (17) 
Prior therapy for primary diagnosis    
   No 
   Yes 
 
10 (29) 
25 (71) 
 
Table 3 Characteristics of enrolled patients 
 
Preliminary indications of efficacy were observed across all hematologic diseases 
studied (Figure 11 and Table 6). 
One patient with AML (evolved from CMML and with a concurrent diagnosis of 
systemic mastocytosis) achieved a complete remission with incomplete blood count 
recovery; bone marrow blast count decreased from 92% to 1%. Five AML patients 
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had a 50% reduction in bone marrow blast counts (20% to 10%, 70% to 20%, 44% 
to 8%, 14% to 7%, 40% to 10%). One patient with low-risk MDS, currently remaining 
on study after 335 days, achieved significant reduction in spleen size and a 
hematologic improvement in platelets (from 98.5 to 369 x10
9
/L) and neutrophils 
(ANC from 410 to 5490), and is no longer granulocyte colony-stimulating factor (G-
CSF) dependent. Five patients with MF attained stable disease; an additional MF 
patient, currently remaining on study after 385 days, achieved clinical improvement 
with a >50% reduction in extramedullary disease (spleen size decreased from 10 cm 
to 3.5 cm sustained over 8 weeks). One patient with T3151 lymphoid blast crisis CML 
on study for 115 days achieved a major cytogenetic response with loss of their 
T3151 mutation.  
 
Characteristic (n = 20) 
Poor risk cytogenetics, n (%) 10 (50) 
Type of AML, n (%) 
   De novo 
   Developed from AHD 
   Unknown 
 
8 (40) 
7 (35) 
5 (25) 
Table 4 AML patients characteristics 
 
Treatment duration ranged from 1 to 387 days (AML: 1–266; CML: 1–281; MDS: 2–
335; MF: 44–387 days). One patient discontinued the study due to a treatment-
related adverse event (AE) after 137 days of therapy at the 10 mg dose level (grade 
[G] 3 hemorrhagic gastritis in the setting of chronic proton pump inhibitor 
administration prior to and during the study). One AML patient evolved from CMML 
on 80 mg had a DLT comprising G3 hypoxia and G3 pleural effusion. The majority of 
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AEs were of G1/2 severity; the most frequent treatment-related AEs included 
dysguesia (16%), alopecia (6%), arthralgia (6%), decreased appetite (6%), nausea 
(6%), and vomiting (6%) (Table 5). 
 
Event, n (%) Grade 1 Grade 2 Grade 3 Grade 4 
Dysgeusia 4 (11%) 2 (6%) 0 0 
Alopecia 3 (9%) 0 0 0 
Muscle 
spasms 
1 (3%) 1 (3%) 0 0 
Nausea 2 (6%) 0 0 0 
Vomiting 2 (6%) 0 0 0 
 
Table 5 Adverse Events 
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Figure 11 Bone marrow blast cells percentage in AML enrolled patients 
 
 
 
 
Disease Response Dose(s) 
MDS 
(Low 
Risk) 
Hematologic improvement in platelets and 
neutrophils,   
G-CSF independent  (1 patient) 
40 mg 
MF 
Clinical improvement with ≥50% reduction in 
spleen size  
(1 patient)  
20 mg 
Stable disease (5 patients) 5, 5, 10, 80, 120 mg 
CML 
Major cytogenetic response (1 patient with 
T315I BC CML) 
20 mg 
Table 6 Patients who obtained a clinical and hematological response 
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4.1.1 PK 
 
Preliminary PK parameters for enrolled subjects come from single and multiple 
dosing of Smo inhibitor administration in all cohorts tested (5, 10, 20, 40, 80, 120, 
180, 270, 400, and 600 mg QD) 
70
. 
The drug was rapidly absorbed following oral dosing with a median Tmax of 1 to 2 
hours after single and multiple dose administration. Following attainment of Cmax, 
plasma concentrations of the compound showed a bi-exponential decline. It was  
eliminated with a mean terminal half-life ranging from 17.4 to 34.2 hours. Following 
repeated daily dosing, the drug steady state was achieved by Day 8 and showed a 
median drug accumulation of 1.4 to 2.9 fold, which is consistent with the estimated 
half-life. In general, low to moderate inter-individual variability were observed in 
Cmax and AUC following single and multiple dose administration, though higher 
variability was observed at 180 and 270 mg. 
4.2 Identification of biomarkers related to Hh pathway 
In order to identify new potential clinical biomarkers for the above mentioned Smo-
inhibitor compound,  the leukemia stem cell population (CD34+ cells) collected 
before and after 28 days treatment in the already described first in men phase I 
dose escalation protocol was studied. Highly purified (98%) bone marrow 
hematopoietic progenitor cells (CD34+ populations) were collected and separated 
from 5 AML, 1 MF and 2 CML patients by immunomagnetic separation, and the 
analysis for gene expression profile (GEP) using Affimetrix HG-U133 Plus 2.0 
platform was performed 
71
. 1197 genes resulted differentially expressed between 
CD34+ cells separated from CML samples, collected before and after 28 days of  the 
experimental therapy (Table 7, Table 8, Figure 12). Clustering of their expression 
profiles showed that mostly genes differentially expressed are mainly related to Hh 
signaling, thus providing relevant evidences that the compound really 
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therapeutically targets the Hh pathway. As far as the genes involved in Hh pathway 
are concerned, it was observed that Gas1 and Kif27 were strongly upregulated (fold 
change 1.0947 and 1.12757 respectively; p-value 0.01 and 0.02 respectively) in 
CD34+ leukemia stem cells after 28 days exposure to treatment as compared to 
baseline, suggesting the potential role of these two genes as new biomarkers of 
activity. GAS-1 (growth arrest specific 1 gene) is a Sonic Hedgehog (Shh)-binding 
protein; it acts to sequester Shh and inhibit the Shh signalling pathway. Kif27 
(kinesin family member 27) mainly acts as a negative regulator in the Hh signaling 
pathway, and inhibits the transcriptional activator activity of Gli1 by inhibiting its 
nuclear translocation. Other genes were differentially expressed after ‘ex- vivo’ 
treatment with the molecule as compared to baseline: we observed a down 
regulation of Bcl2 (fold change -1.03004), ABCA2 (fold change -1.08966), LEF1 (fold 
change -1.28457), Gli1 (fold change -1.0775), Smo (fold change -1.07702), and an 
upregulation of Gli2 (fold change 1.08191).  
Table 7 CML- experiment contains 1197 genes with the specified threshold (p-value < 0.05) 
Table 8 AML- experiment contains 589  genes with the specified threshold (p-value < 0.05) 
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Moreover, genes involved in multidrug resistance pathway were found to be 
differently expressed depending on treatment with the described Smo inhibitor 
compound. In details, ABCB1 (fold change 1,46592) and ABCG2 (fold change -
1,16103) are respectively up and down regulated, with a not statistically significant 
p-value (0,35375 and 0,288194 respectively).  
Bcl2 (B-cell lymphoma 2), Bcl2l2 (Bcl2-like protein 2) and Bcl2l13 (Bcl2-like 13) are 
the founding members of the Bcl-2 family of apoptosis regulator proteins. Recent 
studies showed that Hh signals upregulate Bcl2 to promote cellular survival.  
Casp 4,7,10 (Caspases, or cysteine-aspartic proteases) are a family of cysteine 
proteases that play essential roles in apoptosis, necrosis, and inflammation.  
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Different expression if genes involved in Hh pathway in samples of patients treated with 
Smo-inhibitor compound. Comparison at different timepoints. 
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ABCA2 (ATP-binding cassette sub-family A member 2), ABCF1 (ATP-binding cassette 
sub-family F member 1), ABCB1 (ATP-binding cassette sub-family B member 1, 
MDR1), ABCG2 (ATP-binding cassette sub-family G member 2) belong to the 
superfamily of adenosine triphosphate-binding cassette (ABC) transporters. ABC 
proteins transport various molecules across extra- and intracellular membranes. 
One mechanism of MDR is the increased expression of ABC drug transporters that 
mediate energy-dependent transport of drugs out of the cells against a 
concentration gradient, resulting in low intracellular drug concentrations. This is a 
common finding in LSC, and represents an important clinical problem for disease 
eradication.  
Furthermore, we evaluated Gli1, Gli2 and Smo expression by GEP, comparing data 
before and after 28 days of treatment with SMO-INHIBITOR and, as expected, we 
observed a down regulation of Gli1 (fold change -1.0775), Smo (fold change -
1.07702), and an up regulation of Gli2 (fold change 1.08191).  
Our results suggest that the compound  is able to revert MRD mechanisms of LSC by 
a strong down regulation of genes (Bcl-2, Bcl-2l13, Bcl-2l2, ABCA2, and ABCF1), 
which are critical for chemoresistance in acute and chronic leukemia patients
72
. 
Therefore, the combination of SMO-INHIBITOR with Tyrosine Kinase inhibitors or 
conventional chemotherapy could represent a valid new therapeutic approach in 
these haematological malignancies. 
 
 
4.3 Rationale for combination approach based on Smo inhibitors 
and TKIs in Ph+ Leukemias 
 
Pre-clinical studies showed that the compound has significant activity in imatinib 
resistant CML blast crisis disease (C. Jamieson et al, personal communication).  
Patient derived CD34+ imatinib resistant blast crisis CML cells xenotransplanted into 
immunocompromised mice treated with the drug alone or in combination with 
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dasatinib significantly reduced primary leukemic tumor burden.  This combination 
therapy also was able to reduce the leukemic stem cell population.  In addition, 
treatment with the molecule alone as compared to vehicle reduced leukemic tumor 
formation in secondary recipients, suggesting that the drug is able to inhibit the LSC 
population necessary for tumor propagation.  Finally, treatment with single agent  in 
a CML model of T315I ABL mutant disease (known to have escaped TKI inhibition 
and for which no therapeutic options other than stem cell transplant exist) 
significantly reduced leukemic tumor burden, suggesting that the drug may be a 
viable option for these patients. Similar data have been demonstrated for other 
TKI’s including nilotinib in combination with hedgehog inhibitors. 
Other compounds, also in our experience, have been administered, in clinical trials, 
in association with TKIs in Philadelphia positive Leukemias, resistant or refractory to 
TKIs alone. The rational was based on preclinical data, showing a synergistic activity, 
due to a double inhibition both on BCR-ABL domain and on self-renewal pathways. 
Data regarding our little experience on this topic are not available yet.  
 
4.4 Pre-clinical studies 
 
As previously reported, cumulative evidence coming from literature suggests that 
dormant self-renewing LSC contribute to relapse and blast crisis transformation by 
evading therapies that target cycling cells. Sonic hedgehog signaling was shown to 
modulate cell cycle regulation and self-renewal in normal mouse hematopoietic 
stem cells. However, its role in human LSC regeneration and quiescence had not 
been elucidated. This aim has been investigated (data submitted) in order to 
evaluate the role of Shh signaling in maintenance of dormancy 
73
. Compared to 
chronic phase CML and normal progenitors, human blast crisis LSC harbor enhanced 
expression of the Shh transcriptional activator, GLI2, and decreased expression of a 
transcriptional repressor, GLI3. Treatment of human blast crisis LSC engrafted RAG2
-
55 
 
/-
gc
-/-
 mice with the selective Shh inhibitor, reduced leukemic burden in a niche-
dependent manner commensurate with GLI downregulation. Full transcriptome RNA 
sequencing performed on FACS-purified human progenitors from Smo-inhibitor 
treated blast crisis LSC engrafted mice demonstrated greater Shh gene splice 
isoform concordance with normal progenitors than vehicle treated controls. In 
addition, RNA sequencing revealed significantly decreased cell cycle regulatory 
genes expression and splice isoform analysis demonstrated reversion towards a 
normal splice isoform signature for many cell cycle regulatory genes. Moreover, cell 
cycle FACS analysis showed that selective Shh inhibition permitted dormant blast 
crisis LSC to enter the cell cycle while normal progenitor cell cycle status was 
unaffected. Finally, the drug synergized with BCR-ABL inhibition to reduce blast crisis 
LSC survival and self-renewal in concert with increased expression of Shh pathway 
regulators. Therefore selective Shh antagonism induces cycling of dormant human 
blast crisis LSC, rendering them susceptible to BCR-ABL inhibition, while sparing 
normal progenitors. Implementation of novel LSC splice isoform detection platforms 
to assess efficacy of Shh inhibitor-mediated sensitization to molecularly targeted 
therapy may inform dormant cancer stem cell elimination strategies that ultimately 
avert relapse.  
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5.Discussion  
  
Current available treatments in many haematological malignancies are still 
unsatisfactory, in terms of overall response rates and long term survival. In 
particular, as  widely demonstrated, the complex molecular heterogeneity of AML 
requires the identification of molecular targets in order to perform tailored 
treatments approaches.  At the same time, the mechanisms of resistance to TKIs in 
Philadelphia positive leukemias underline the need for the assessment of other 
targets, to be hit in order to obtain not only a deeper control of the disease but also 
to eradicate it definitely. 
Therefore, the so called “cell of origin” key concept is assuming a more and more 
important role in the understanting of pathogenetic events which lead to the onset 
of leukemias. We know, infact, that in many cases of AML and CML, the first 
triggering neoplastic event occur to the most immature cell of the HSC, giving rise to 
a kind of leukemia intrinsically chemoresistant. Many molecular pathways seem to 
be involved in self renewal of the LSC, and among these the Hedgehog signalling was 
demonstrated to play a key role. 
Many compounds are currently in clinical development, both in solid and in 
haematological neoplasia, showing preliminary promising results as single agents. 
No data were available, so far, on leukemias.  
We’ve therefore participated in a first in man Phase I clinical trial, aimed, by 
definition, to define the safety profile in terms of adverse events of a new Smo 
antagonist compound, administered mainly at AML and CML relapsed or refractory 
patients.  The drug was safe and well tolerated, with early signs of efficacy observed 
in all hematologic diseases studied. Several patients with aggressive malignancies 
remained on trial for prolonged durations with improved quality of life; some 
exhibited cellular differentiation as determined by flow cytometry. On-target AEs 
(e.g. dysgeusia and alopecia) were observed at multiple dose levels. 
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Pharmacokinetics were linear, predictable, and compatible with once-daily dosing.  
The limited number of patients enrolled, of course, requires further investigations in 
order to confirm these data.  
The biological correlative studies have shown relevant results as well. Through the 
GEP analysis, performed on CD34+ separated CML or AML cells, before and after 
one month of therapy, a statistically different expression signature was found. The 
involvement of genes belonging to Hh pathway allowed us to confirm that the drug 
is active against the pathway it has been synthetized for. Moreover, our data 
demonstrate that the drug is reverts MDR by down-regulation of ABCA2 and BCL2 
on leukemia stem cells in AML and CML treated patients. It’s worldwide shared the 
challenge on MDR, mainly in elderly AML patients, with intrinsically resistant 
leukemias. Based on this, at least in this poor prognostic group, a combinatory 
approach consisting in Smo-inhibitor and chemotherapy could offer a relevant 
benefit to our patients with high risk AML or relapsed CML. Starting from this 
rationale, we’re planning to participate in a second clinical trial, which is based on 
the concomitant administration of Smo-inhibitor compound and Cyatarabine in high 
risk AML patients.  
In conclusion, in the landscape of  the molecular pathways involved in 
leukemogenesis, the Hh pathway seems to have a key role in self renewal, as 
demonstrated by our biological experiments in terms of up and down regulation of 
specific pathway genes. A combination approach with some “milestones” drugs of 
leukemia might lead, through the applicability of a strong rationale, to the 
improvement of the clinical outcome of our patients.   
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